Welcome to our dedicated page for Serina Therapeutics SEC filings (Ticker: SER), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Serina Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Serina Therapeutics's regulatory disclosures and financial reporting.
Serina Therapeutics’ major shareholder group led by Juvenescence Limited and JuvVentures (UK) Limited reports beneficial ownership of 4,400,781 shares of common stock of Serina Therapeutics, Inc. This includes 3,267,188 shares held directly and shares issuable upon exercise of Replacement Incentive Warrants and Incentive Warrants.
The filing states this position represents approximately 27.3% of Serina’s common stock, calculated using 14,997,505 shares outstanding as of May 10, 2026 and giving effect to warrant exercises and two tranches of new shares described in Item 6. A $15.0 million private placement funded on March 20, 2026 by other investors caused more than a 1% change in this ownership percentage; the reporting persons did not participate and report no other Serina stock transactions in the past 60 days aside from arrangements referenced in Item 6.
Serina Therapeutics, Inc. director Stephen K. Brannan reported an open-market purchase of common stock. On July 7, 2026, he bought 1,000 shares of Serina Therapeutics common stock at a price of $2.03 per share. After this transaction, he directly holds 1,000 shares.
Serina Therapeutics, Inc. reported that stockholders approved a major amendment to its charter, increasing authorized common stock from 40,000,000 to 125,000,000 shares effective June 17, 2026. This gives the company significantly more capacity to issue new shares in the future.
At the 2026 Annual Meeting, stockholders elected three directors to terms ending at the 2029 meeting. They also approved adding 2,000,000 shares to the 2024 Equity Incentive Plan, authorized issuances of common stock tied to conversion of Series A Preferred Stock and certain private placement securities, supported executive compensation and annual say‑on‑pay votes, and ratified Frazier & Deeter, LLC as auditor for 2026.
Serina Therapeutics director Jay Venkatesan reported multiple equity-related transactions. A trust associated with him, The Jay Venkatesan Legacy Trust, acquired 224,152 shares of common stock on mandatory conversion of 96,525 shares of Series A Convertible Preferred Stock at an adjusted conversion price of $2.25 per share, including 1,930 shares issued for accrued dividends. Following this, the trust held 231,705 common shares indirectly. Venkatesan also received a grant of 15,250 stock options with a $1.98 exercise price expiring in 2036, which will vest around the next annual meeting, and he bought 589 common shares in an open‑market transaction at $1.78 per share. A footnote notes an earlier administrative error that misclassified certain holdings between direct and indirect ownership.
Serina Therapeutics director Gregory Bailey reported a series of stock acquisitions and conversions tied to prior financing agreements and equity awards. On June 17, 2026, 762,548 shares of Series A Convertible Preferred Stock were mandatorily converted into 1,755,555 shares of common stock, plus 15,250 additional shares issued as accrued dividends, after stockholders approved the conversion terms.
Separate transactions show common stock issued upon automatic conversion of Pre-Funded Warrants originally purchased at $2.2499 per warrant under a March 17, 2026 Securities Purchase Agreement, following stockholder approval obtained on June 17, 2026. Bailey also received 3,333,333 redeemable warrants with a $5.00 exercise price and 15,250 stock options with a $1.98 exercise price as additional derivative awards.
Serina Therapeutics, Inc. director Stephen K. Brannan received a grant of stock options covering 15,250 shares of common stock. The options have an exercise price of $1.98 per share and expire on June 17, 2036. They vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the June 17, 2026 grant date, subject to his continued service with the company. Following this grant, he holds 15,250 stock options, reflecting a routine compensation-related award rather than an open-market trade.
Serina Therapeutics, Inc. reported that director Karen J. Wilson received a grant of stock options covering 15,250 shares of common stock at an exercise price of $1.98 per share. These options expire on June 17, 2036 and relate to 15,250 underlying common shares.
According to the footnotes, the options will vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the grant date, subject to her continued service. A separate row shows she beneficially owns 30,100 common shares, which is an updated holding and not a new transaction.
Serina Therapeutics, Inc. director Marshall Richard Peter reported receiving a grant of stock options covering 15,250 shares of common stock. The options have an exercise price of $1.98 per share and expire on June 17, 2036.
According to the filing, the options vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the grant date, subject to his continued service with the company. Following this grant, he holds 15,250 stock options directly from this award.
Serina Therapeutics director Karen J. Wilson bought additional common stock in two recent open-market purchases. She acquired 5,100 shares on June 11, 2026 at a weighted average price of $1.745 per share and 5,000 shares on June 12, 2026 at a weighted average price of $1.77 per share. After these transactions, she directly owns 10,100 shares of Serina Therapeutics common stock. The filing notes that each day’s price reflects multiple trades within narrow ranges around the reported averages.